Moomoo AI 已提取核心信息
Avalo Therapeutics, Inc., a biotechnology company, has been the subject of a recent Schedule 13G/A filing with the Securities and Exchange Commission (SEC) as of December 31, 2023. The filing was made by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen, indicating a shared voting and dispositive power over 2,500 shares of Avalo Therapeutics' common stock, issuable upon exercise of warrants. These shares represent a 0.3% ownership of the class. The filing entities have entered into a Joint Filing Agreement, suggesting a coordinated approach to the filing. The address for Point72 Asset Management and Point72 Capital Advisors is in Stamford, CT, and both entities are organized under the laws of Delaware. Steven A. Cohen is identified as a United States citizen. The filing...Show More
Avalo Therapeutics, Inc., a biotechnology company, has been the subject of a recent Schedule 13G/A filing with the Securities and Exchange Commission (SEC) as of December 31, 2023. The filing was made by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen, indicating a shared voting and dispositive power over 2,500 shares of Avalo Therapeutics' common stock, issuable upon exercise of warrants. These shares represent a 0.3% ownership of the class. The filing entities have entered into a Joint Filing Agreement, suggesting a coordinated approach to the filing. The address for Point72 Asset Management and Point72 Capital Advisors is in Stamford, CT, and both entities are organized under the laws of Delaware. Steven A. Cohen is identified as a United States citizen. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics and were not acquired in connection with any transaction having such purpose or effect. The filing includes a certification of accuracy and completeness signed by Jason M. Colombo, an authorized person for all three reporting entities.
截至2023年12月31日，生物技术公司Avalo Therapeutics, Inc. 已成为最近向美国证券交易委员会（SEC）提交的附表13G/A文件的主题。该文件由Point72资产管理有限责任公司、Point72 Capital Advisors, Inc.和Steven A. Cohen提交，表明行使认股权证后可发行的2,500股Avalo Therapeutics普通股拥有共同的投票权和处置权。这些股份占该类别0.3％的所有权。申报实体已签订联合申报协议，建议采用协调的申报方法。Point72资产管理公司和Point72 Capital Advisors的地址位于康涅狄格州斯坦福德...展开全部
截至2023年12月31日，生物技术公司Avalo Therapeutics, Inc. 已成为最近向美国证券交易委员会（SEC）提交的附表13G/A文件的主题。该文件由Point72资产管理有限责任公司、Point72 Capital Advisors, Inc.和Steven A. Cohen提交，表明行使认股权证后可发行的2,500股Avalo Therapeutics普通股拥有共同的投票权和处置权。这些股份占该类别0.3％的所有权。申报实体已签订联合申报协议，建议采用协调的申报方法。Point72资产管理公司和Point72 Capital Advisors的地址位于康涅狄格州斯坦福德，这两个实体均根据特拉华州法律组建。史蒂芬·科恩被确定为美国公民。该文件称，收购这些股份不是为了改变或影响Avalo Therapeutics的控制权，也不是与任何具有此类目的或效果的交易有关而收购的。该文件包括一份由所有三个申报实体的授权人Jason M. Colombo签署的准确性和完整性证明。
有用
没用